The new signaling pathway ERK5/TP53INP2 sensitizes cancer cells to death-receptor agonists and Natural Killer cells

Abstract

[1]  A. Muntasell,et al.  Adaptive NK cell response to human cytomegalovirus: Facts and open issues. , 2022, Seminars in immunology.

[2]  H. Walczak,et al.  Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries , 2022, Cell Death & Differentiation.

[3]  C. Moiola,et al.  Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool , 2022, International journal of molecular sciences.

[4]  J. Lizcano,et al.  An ERK5–KLF2 signalling module regulates early embryonic gene expression and telomere rejuvenation in stem cells , 2021, The Biochemical journal.

[5]  J. Trovik,et al.  Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis , 2021, Communications Medicine.

[6]  D. Dinsdale,et al.  Cryo-EM structural analysis of FADD:Caspase-8 complexes defines the catalytic dimer architecture for co-ordinated control of cell fate , 2021, Nature Communications.

[7]  D. Wainwright,et al.  NK cell-based cancer immunotherapy: from basic biology to clinical development , 2021, Journal of Hematology & Oncology.

[8]  Á. Payer,et al.  Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer , 2020, International journal of molecular sciences.

[9]  D. M. Pereira,et al.  Targeted Avenues for Cancer Treatment: The MEK5-ERK5 Signaling Pathway. , 2020, Trends in molecular medicine.

[10]  C. Watzl,et al.  Mechanisms of natural killer cell‐mediated cellular cytotoxicity , 2019, Journal of leukocyte biology.

[11]  R. Gomis,et al.  Regulation of death receptor signaling by the autophagy protein TP53INP2 , 2019, The EMBO journal.

[12]  S. Ramakrishna,et al.  CRISPR-mediated upregulation of DR5 and downregulation of cFLIP synergistically sensitize HeLa cells to TRAIL-mediated apoptosis. , 2019, Biochemical and biophysical research communications.

[13]  B. Stecca,et al.  Impact of ERK5 on the Hallmarks of Cancer , 2019, International journal of molecular sciences.

[14]  Z. Zeng,et al.  Natural killer group 2D receptor and its ligands in cancer immune escape , 2019, Molecular cancer.

[15]  Laura E. Herring,et al.  KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. , 2018, Cancer cell.

[16]  M. McKeown,et al.  Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. , 2018, ACS chemical biology.

[17]  H. Walczak,et al.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy , 2017, Nature Reviews Cancer.

[18]  D. Green,et al.  Caspase‐8: regulating life and death , 2017, Immunological reviews.

[19]  S. Schmid,et al.  TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation , 2017, Proceedings of the National Academy of Sciences.

[20]  Y. Hu,et al.  ERK5 kinase activity is dispensable for cellular immune response and proliferation , 2016, Proceedings of the National Academy of Sciences.

[21]  N. Gómez,et al.  ERK5 and Cell Proliferation: Nuclear Localization Is What Matters , 2016, Front. Cell Dev. Biol..

[22]  T. Carvalho,et al.  MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism , 2016, Oncotarget.

[23]  B. Shankar,et al.  Potential Role of TRAIL in Metastasis of Mutant KRAS Expressing Lung Adenocarcinoma , 2016, Cancer Microenvironment.

[24]  N. Gray,et al.  The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma , 2014, Gut.

[25]  H. Walczak,et al.  Getting TRAIL back on track for cancer therapy , 2014, Cell Death and Differentiation.

[26]  M. Palacín,et al.  Autophagy-regulating TP53INP2 mediates muscle wasting and is repressed in diabetes. , 2014, The Journal of clinical investigation.

[27]  A. Esparís-Ogando,et al.  Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor , 2013, Clinical Cancer Research.

[28]  H. Pass,et al.  Extracellular Signal–Regulated Kinase 5: A Potential Therapeutic Target for Malignant Mesotheliomas , 2013, Clinical Cancer Research.

[29]  N. Gómez,et al.  Canonical and Kinase Activity-Independent Mechanisms for Extracellular Signal-Regulated Kinase 5 (ERK5) Nuclear Translocation Require Dissociation of Hsp90 from the ERK5-Cdc37 Complex , 2013, Molecular and Cellular Biology.

[30]  D. Lawrence,et al.  TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. , 2012, Molecular cell.

[31]  S. Fulda,et al.  ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells , 2012, Cell Death and Disease.

[32]  Louise Fairall,et al.  A Death Effector Domain Chain DISC Model Reveals a Crucial Role for Caspase-8 Chain Assembly in Mediating Apoptotic Cell Death , 2012, Molecular cell.

[33]  K. Iverfeldt,et al.  TRAIL resistance in human neuroblastoma SK-N-AS cells is dependent on protein kinase C and involves inhibition of caspase-3 proteolytic processing , 2012, Journal of Neuro-Oncology.

[34]  J. Yates,et al.  BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction , 2012, Oncogene.

[35]  E. Gottlieb,et al.  BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane , 2011, Cell Death and Differentiation.

[36]  C. Rancourt,et al.  Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation , 2010, Oncogene.

[37]  F. Mansilla,et al.  The nuclear cofactor DOR regulates autophagy in mammalian and Drosophila cells , 2010, EMBO reports.

[38]  J. Montero,et al.  Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target , 2009, PloS one.

[39]  D. Lawrence,et al.  Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling , 2009, Cell.

[40]  R. Hipskind,et al.  ERK5 Knockdown Generates Mouse Leukemia Cells with Low MHC Class I Levels That Activate NK Cells and Block Tumorigenesis1 , 2009, The Journal of Immunology.

[41]  M. Kashem,et al.  Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. , 2008, Biochemical and biophysical research communications.

[42]  Philip R. Cohen,et al.  Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer , 2008, Oncogene.

[43]  J. Montero,et al.  Erk5 is activated and acts as a survival factor in mitosis. , 2007, Cellular signalling.

[44]  A. Esparís-Ogando,et al.  Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. , 2007, Cellular signalling.

[45]  P. Lipsky,et al.  TRAF6 Regulates Cell Fate Decisions by Inducing Caspase 8-dependent Apoptosis and the Activation of NF-κB* , 2006, Journal of Biological Chemistry.

[46]  E. Nishida,et al.  Regulation of Nuclear Translocation of Extracellular Signal-Regulated Kinase 5 by Active Nuclear Import and Export Mechanisms , 2006, Molecular and Cellular Biology.

[47]  Chun Guo,et al.  Targeted Deletion of mek5 Causes Early Embryonic Death and Defects in the Extracellular Signal-Regulated Kinase 5/Myocyte Enhancer Factor 2 Cell Survival Pathway , 2005, Molecular and Cellular Biology.

[48]  B. Berk,et al.  Big Mitogen-Activated Protein Kinase (BMK1)/ERK5 Protects Endothelial Cells From Apoptosis , 2004, Circulation research.

[49]  F. López‐Soriano,et al.  Mice lacking TNFα receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody , 2003, Cell Death and Differentiation.

[50]  Serge Batalov,et al.  Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. , 2003, Molecular cell.

[51]  P. Cohen,et al.  An analysis of the phosphorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. , 2003, The Biochemical journal.

[52]  R. K Srivastava,et al.  Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer , 2001, Oncogene.

[53]  X. Liu,et al.  An APAF-1·Cytochrome c Multimeric Complex Is a Functional Apoptosome That Activates Procaspase-9* , 1999, The Journal of Biological Chemistry.

[54]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[55]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[56]  M. Peter,et al.  Bcl-xL Acts Downstream of Caspase-8 Activation by the CD95 Death-inducing Signaling Complex* , 1998, The Journal of Biological Chemistry.

[57]  Jiahuai Han,et al.  BMK1/ERK5 regulates serum‐induced early gene expression through transcription factor MEF2C , 1997, The EMBO journal.

[58]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[59]  S. Yonehara,et al.  Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. , 1996, Journal of immunology.

[60]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[61]  M. Burow,et al.  MEK5/ERK5 pathway: the first fifteen years. , 2012, Biochimica et biophysica acta.

[62]  M. Rue,et al.  Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. , 2004, The Journal of pathology.